Pipeline
A pipeline built on one platform
Pear intends to obtain FDA clearance for each investigational prescription digital therapeutic in its development pipeline.
| Program | Indication | Status | Notes |
|---|---|---|---|
| reSET® | Substance Use Disorder (SUD) | FDA-cleared | 12-week prescription-only therapeutic, adjunct to outpatient treatment. |
| reSET-O™ | Opioid Use Disorder (OUD) | In development | Designed alongside medication-assisted outpatient treatment. |
| THRIVE™ | Schizophrenia | In development | Therapeutic software targeting symptom management and adherence. |
| reCALL™ | Combat post-traumatic stress disorder (PTSD) | In development | Evidence-based trauma-focused therapy delivered digitally. |
| reVIVE™ | General anxiety disorder (GAD) | In development | Structured cognitive and behavioral therapy program. |
| Undisclosed | Chronic pain | Early development | Behavioral therapeutic as an adjunct to pain management. |
| Undisclosed | Major depressive disorder (MDD) | Early development | Digital therapy integrated with standard antidepressant care. |
| Undisclosed | Insomnia | Early development | Sleep-focused behavioral therapeutic program. |
Investigational products are not available for prescription and their safety and effectiveness have not been established by the FDA.